1. Home
  2. ARKO vs CTNM Comparison

ARKO vs CTNM Comparison

Compare ARKO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARKO Corp.

ARKO

ARKO Corp.

N/A

Current Price

$4.74

Market Cap

490.3M

Sector

Energy

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$17.17

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARKO
CTNM
Founded
1970
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
490.3M
550.7M
IPO Year
2021
2024

Fundamental Metrics

Financial Performance
Metric
ARKO
CTNM
Price
$4.74
$17.17
Analyst Decision
Buy
Buy
Analyst Count
2
4
Target Price
$7.50
$19.00
AVG Volume (30 Days)
1.2M
534.3K
Earning Date
05-07-2026
05-13-2026
Dividend Yield
1.91%
N/A
EPS Growth
15.38
0.46
EPS
N/A
N/A
Revenue
$9,142,799,000.00
N/A
Revenue This Year
$12.86
N/A
Revenue Next Year
$1.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.26
N/A
52 Week Low
$3.71
$8.60
52 Week High
$8.76
$17.51

Technical Indicators

Market Signals
Indicator
ARKO
CTNM
Relative Strength Index (RSI) 36.34 62.30
Support Level $4.20 $13.65
Resistance Level $5.26 N/A
Average True Range (ATR) 0.19 0.86
MACD 0.11 0.07
Stochastic Oscillator 65.19 96.43

Price Performance

Historical Comparison
ARKO
CTNM

About ARKO ARKO Corp.

ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. It derives the majority of its revenue from retail and wholesale distribution of fuel.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: